Comparison of Multilabel and Single-Label Classification Applied to the Prediction of the Isoform Specificity of Cytochrome P450 Substrates

被引:47
|
作者
Michielan, Lisa [1 ]
Terfloth, Lothar [2 ]
Gasteiger, Johann [2 ,3 ,4 ]
Moro, Stefano [1 ]
机构
[1] Univ Padua, MMS, Dipartimento Sci Farmaceut, I-35131 Padua, Italy
[2] Mol Networks GmbH, D-91052 Erlangen, Germany
[3] Univ Erlangen Nurnberg, Comp Chem Ctr, D-91052 Erlangen, Germany
[4] Univ Erlangen Nurnberg, Inst Organ Chem, D-91052 Erlangen, Germany
关键词
IN-SILICO; DRUG-METABOLISM; MODELS; P450; AUTOCORRELATION; ADDITIVITY; ENZYME; 3A4; 2D6;
D O I
10.1021/ci900299a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Each drug can potentially be metabolized by different CYP450 isoforms. In the development of new drugs, the prediction of the metabolic fate is important to prevent drug-drug interactions. In the present study, a collection of 580 CYP450 substrates is deeply analyzed by applying multi- and single-label classification strategies, after the computation and selection of suitable molecular descriptors. Cross-training with support vector machine, multilabel k-nearest-neighbor and counterpropagation neural network modeling methods were used in the multilabel approach, which allows one to classify the compounds simultaneously in multiple classes. In the single-label models, automatic variable selection was combined with various cross-validation experiments and modeling techniques. Moreover, the reliability of both multi- and single-label models was assessed by the prediction of an external test set. Finally, the predicted results of the best models were compared to show that, even if the models present similar performances, the multilabel approach more coherently reflects the real metabolism information.
引用
收藏
页码:2588 / 2605
页数:18
相关论文
共 50 条
  • [41] Prediction of cytochrome p450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines
    Yap, CW
    Chen, YZ
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2005, 45 (04) : 982 - 992
  • [42] Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study
    Desch, Michael
    Schlecker, Christina
    Hohl, Kathrin
    Liesenfeld, Karl-Heinz
    Chan, Tom
    Mueller, Fabian
    Wunderlich, Glen
    Keller, Sascha
    Ishiguro, Naoki
    Wind, Sven
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2023, 43 (02) : 113 - 121
  • [43] PHARMACOKINETICS OF CYTOCHROME P450 PROBE SUBSTRATES IN HEALTHY SUBJECTS AND PSORIASIS PATIENTS: A MODEL-BASED COMPARISON TO INFORM THERAPEUTIC PROTEINS-DRUGS INTERACTION POTENTIAL.
    Mohamed, M.
    Sathe, A.
    Othman, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S38 - S38
  • [44] Prediction of Human Hepatic Clearance for Cytochrome P450 Substrates via a New Culture Method Using the Collagen Vitrigel Membrane Chamber and Fresh Hepatocytes Isolated from Liver Humanized Mice
    Watari, Ryuji
    Kakiki, Motoharu
    Yamasaki, Chihiro
    Ishida, Yuji
    Tateno, Chise
    Kuroda, Yukie
    Ishida, Seiichi
    Kusano, Kazutomi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2019, 42 (03) : 348 - 353
  • [45] Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common marmosets genotyped for P450 2C19
    Matsumoto, Shogo
    Uehara, Shotaro
    Kamimura, Hidetaka
    Ikeda, Hiroshi
    Maeda, Satoshi
    Hattori, Machiko
    Nishiwaki, Megumi
    Kato, Kazuhiko
    Yamazaki, Hiroshi
    XENOBIOTICA, 2021, 51 (04) : 479 - 493
  • [46] Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations
    Huth, Felix
    Gardin, Anne
    Umehara, Kenichi
    He, Handan
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (05) : 1113 - 1124
  • [47] Cinacalcet Does Not Affect the Activity of Cytochrome P450 3A Enzymes, a Metabolic Pathway for Common Immunosuppressive AgentsA Randomized, Open-Label, Crossover, Single-Centre Study in Healthy Volunteers
    Desmond Padhi
    Maggi Salfi
    Maurice Emery
    Drugs in R & D, 2008, 9 : 335 - 343
  • [48] Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents - A randomized, open-label, crossover, single-centre study in healthy volunteers
    Padhi, Desmond
    Salfi, Maggi
    Emery, Maurice
    DRUGS IN R&D, 2008, 9 (05) : 335 - 343
  • [49] Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial
    Han, Sang Won
    Kim, Yong-Jae
    Ahn, Seong Hwan
    Seo, Woo-Keun
    Yu, Sungwook
    Oh, Seung-Hun
    Kim, Youn Nam
    Lee, Kyung-Yul
    INTERNATIONAL JOURNAL OF STROKE, 2016, 11 (04) : 485 - 491
  • [50] Comparison of rat and human cytochrome P450 (CYP) sources of N-alkylprotoporphyrin -: IX.: Formation after interaction with porphyrinogenic xenobiotics:: studies with cDNA-expressed single CYP enzymes
    Gamble, JT
    Nakatsu, K
    Marks, GS
    XENOBIOTICA, 2002, 32 (11) : 997 - 1006